Heron Therapeutics Separates Chairman & CEO Roles; Barry Quart Departs

Heron Therapeutics, Inc. HRTX announced the appointment of Craig Collard as Chief Executive Officer (CEO), effective immediately.
Collard succeeds Barry Quart, Pharm.D., who has stepped down as CEO and Chairman of the Board.
In addition, Adam Morgan was elected Chairman of the company's Board of Directors. The positions of Chairman and CEO will now be separate, and the board's size will also be reduced to seven members.
Collard brings more than three decades of experience leading innovative pharmaceutical companies. Most recently, he served as CEO of Veloxis Pharmaceutics A/S before its acquisition by Asahi Kasei Corp.
Price Action: HRTX shares are trading higher by 17.54% at $1.7750 on the last check Monday.

Momentum33.80

GrowthNot Available

QualityNot Available

Value4.64

Short

Medium

Long